Investors
KronosMD is raising under Regulation Crowdfunding
Series CF Preferred Stock at $1.00 per share, from $500, only through PicMii dba Highlander Crowdfunding. Everything you are entitled to see is on this page or on the offering page.
Pre-revenue · Not FDA cleared
KronosMD in four questions
01 · The problem
Between checkups, dentists cannot see cavities, gum disease or bone loss developing.
Remote tools use phone photos, which show only the surface. X-rays see beneath it but need an office visit and use radiation. 42% of U.S. adults 30+ have gum disease.
02 · Why we believe we can compete
An issued, cited patent, a prototype that already images a full arch, and no at-home sub-surface product on the market.
CEO with 40+ years in dentistry; an adviser who took an oral device through FDA clearance; ~350 shareholders, about half dentists. Competitors are larger and better funded.
03 · How we intend to make money
Mainly direct to consumers; also through dentists and DSOs.
S-WAVE™ tray about $350 · subscription about $1 a day · in-app oral-care products. Requires FDA authorization for home use; pricing untested; no revenue until then.
04 · What $5M is intended to fund
Software & AI $1.51M · Hardware $1.50M · G&A $500K · Regulatory & FDA $400K · Marketing $350K · Legal $300K · Portal fee $245K · Patents $200K.
At $1M we hire the team; at $5M we complete verification and submit to the FDA for home use. More capital will be needed to launch.
Summarized from the KronosMD, Inc. Form C (Investor Summary, Business Model and Use of Proceeds). Allocations shown at the $5,000,000 maximum and may change. Investing involves a high degree of risk; you could lose your entire investment.
Business model
How it works, and what it costs
Place the tray, tap scan
Minutes at home; all sensors fire at once, the whole arch in one shot.
Software compares with last month
AI being designed to flag change early.
A dentist reviews what is flagged
Telehealth dentists contracted by KronosMD, or your own practice.
S-WAVE™ tray, one-time
monitoring, reviewed by a dentist
oral-care products matched to your scans
Who buys
Consumers first, especially people in aligner treatment; then dentists and DSOs for their patients; later, possible licensing to aligner companies (no agreements today). Market context: Align Technology cites a 600M-consumer opportunity and shipped 2.6M aligner cases in 2025; 56% of people have some malocclusion.
Pricing is a plan and untested; no customer has paid for S-WAVE™. Requires FDA authorization for home use. Align Technology figures from its Q4/FY2025 results and 2025 Form 10-K; Lombardo et al. 2020 for malocclusion prevalence; not independently verified.
Competition
No one offers at-home, below-the-surface 3D imaging today
In office · below the surface
X-ray / CBCT makers
Planmeca, Dentsply Sirona, Carestream, Vatech. Radiation, an office visit, thousands of dollars.
At home · below the surface
S-WAVE™ (in development)
Full arch, teeth, gums and bone, from a tray at home. To our knowledge, no product on the market.
In office · surface only
Intraoral scanners
Align iTero, 3Shape, Medit. Tooth shape for aligners and crowns; nothing beneath.
At home · surface only
Phone-photo monitoring
DentalMonitoring: 2M+ patients, ~$100M raised in 2026. Proved people will scan at home and pay monthly, with photos.
What this means
- The incumbents sell to dentists and need a visit.
- Photo-monitoring proved the subscription and the FDA path for AI software; it can’t see below the surface.
- Our edge: an issued, cited patent, acquired research data and a prototype that already images a full arch.
- Our risk: they are bigger and better funded, and S-WAVE™ is untested in people.
Company names are trademarks of their owners, for identification only. DentalMonitoring figures from its public announcements (Feb. 2026), not independently verified. Positions reflect KronosMD’s assessment of publicly described products.
The offering
Own a piece of S-WAVE™. And more of it.
per share, Series CF Preferred
minimum investment
offering closes
for everyone, $500 or $100,000
Bonus shares: invest more, own more
+20% on any amount in the first 7 days (10% in days 8–21). Plus, by amount invested, combined cap 40%:
What your money builds
Use of proceeds at $5M, per the Form C
Up to $5,000,000 only through PicMii dba Highlander Crowdfunding. Bonus shares per the Form C: 20% days 1–7, 10% days 8–21, plus 10/15/20% at $2K/$5K/$10K, combined cap 40%. Series CF Preferred carries an 8% dividend only if and when declared by the board (none has been paid) and votes by proxy through the CEO; see the Form C. Milestones are plans at each funding level and may change; use of proceeds is detailed in the Form C. The shares may never be worth more than you pay. Read the Form C and its risk factors before investing.
How to invest
Four steps, about ten minutes
At invest.highlander.ai/swave. The Form C, risk factors and audited financials are the offering; this page only summarizes them.
Identity check required by law. Non-accredited investors have annual Reg CF limits; the portal calculates yours.
From $500. The typical Reg CF investment in 2025–26 was about $1,700–$2,000 (industry data). Bonus shares at $2,000, $5,000 and $10,000 per the Form C. Funds sit in escrow at Enterprise Bank & Trust until closing.
Cancel up to 48 hours before the deadline. After closing, shares are recorded in your name; you receive quarterly updates and the annual report.
Procedures, limits, escrow and cancellation rights are set by Regulation Crowdfunding and the portal and described in the Form C, which controls. Typical investment per Kingscrowd (2025 average $1,716; Q1 2026 $1,840) and Crowdfund Capital Advisors (Q1 2026 about $2,000); context only, not a recommendation of any amount. Nothing here is investment, tax or legal advice.
Who already owns KronosMD
About 350 shareholders, 36 states, 7 countries
led by Oregon, Washington, New York, California and Florida
Canada, UK, Australia, Israel, Japan, the Netherlands, Barbados
are dentists, per Company records. If you practice, you already know what you would do with a scan a month.
Counts are shareholder records by mailing address; a holder with more than one account may appear more than once. The existing shareholder base is not an indication that this offering is suitable for you or of any future result.
Investor documents and compliance
Everything you are entitled to see, in one place
Regulation Crowdfunding gives every investor the same disclosures, the same rights and the same protections. This section gathers them so you can research the offering before you invest.
Offering documents
Form C, the offering statement
The legal offering document filed with the SEC: business description, use of proceeds, offering terms, ownership and capital structure, related-party transactions, risk factors and financial statements. It controls over everything on this website. Read it on the portal before investing.
Audited financial statements
Fiscal years 2025 and 2024, audited by an independent PCAOB-registered firm, attached to the Form C as Exhibit A. KronosMD has no revenue and very little cash; the statements show it.
Form C/A amendments
If anything material changes during the offering, the Company files an amendment. A material change gives you five business days to reconfirm your investment; if you do not, it is cancelled and your funds returned.
Amendments appear on the portal and on EDGAR.
Form C-U progress updates
Filed when the offering reaches 50% and 100% of the target, and at closing with the final amount raised.
Series CF Preferred Stock terms
Certificate of Designation: $1.00 per share; 8% dividend only if and when declared by the board (none has been paid); votes by proxy through the CEO; other rights and limitations as set out in the Form C and the subscription agreement.
Subscription agreement and escrow
You sign electronically on the portal. Funds are held by Enterprise Bank & Trust as escrow agent and released to the Company only at closing; if the target is not met by the deadline, funds are returned.
All SEC filings by KronosMD, Inc. are public on EDGAR full-text search (search “KronosMD”).
Your rights
How much you may invest
Non-accredited investors are limited across all Reg CF offerings in any 12 months: if either your annual income or net worth is under $124,000, the greater of $2,500 or 5% of the greater of the two; if both are $124,000 or more, 10% of the greater of the two, up to $124,000. Accredited investors have no limit. The portal calculates your limit from what you enter.
Cancel for any reason
Up to 48 hours before the offering deadline, you can cancel on the portal and your funds are returned. In the final 48 hours a commitment is final, unless the Company makes a material change, which reopens the right.
One-year resale restriction
Shares bought in a Reg CF offering generally cannot be resold for one year, except to the Company, to an accredited investor, to a family member or trust, or in an SEC-registered offering. There is no public market for KronosMD shares and none may develop.
Educational materials and acknowledgment
Before you invest, the portal must give you educational materials on Reg CF and you must confirm that you understand you could lose your entire investment and that you can bear the loss.
Equal information
Every investor sees the same Form C and the same answers. Questions asked on the portal are answered publicly so no investor gets information another does not.
No advice, no guarantees
Neither the Company nor the portal gives investment, tax or legal advice. Nothing on this website is a recommendation of any amount. Bonus shares and milestones are described in the Form C; the shares may never be worth more than you pay.
The funding portal
PicMii Crowdfunding, LLC dba Highlander Crowdfunding
A funding portal registered with the SEC and a member of FINRA. Reg CF offerings may be conducted only through a registered portal or broker-dealer; the Company cannot accept your investment directly.
Check the registration yourself
Funding portals appear in FINRA’s funding-portal directory and the SEC’s list of registered portals. Confirm the portal before you enter payment details.
What the portal does
Hosts the Form C and the public Q&A, runs identity and investment-limit checks, collects commitments into escrow, delivers educational materials, and files progress updates. Its fee (4.9%) is disclosed in the Form C.
What the portal does not do
It does not recommend this investment, verify the Company’s business claims beyond the checks the rules require, or hold your shares after closing. Shares are recorded in your name on the Company’s register.
Company and governance
The issuer
KronosMD, Inc., a Colorado corporation, 1000 Newbury Rd., Suite 290A, Thousand Oaks, California 91320. One full-time employee, the CEO. Officers, directors and principal shareholders are listed in the Form C.
Ownership and capital structure
The Form C sets out every class of stock, the number of shares outstanding, who holds more than 20% of the voting power, and how this offering dilutes existing holders. Read it before you decide what your shares represent.
Related-party transactions
The CEO holds roles at affiliated companies. Any transaction between the Company and an officer, director, major shareholder or their affiliates is disclosed in the Form C, including the 2022 acquisition of the technology paid in KronosMD shares.
Where the technology came from
Acquired in 2022 from the shareholders of the technology’s original developer, a company with which KronosMD has no affiliation. The Form C describes the acquisition and the related risk factors, including third-party patents in intraoral ultrasound.
Bad-actor check
Reg CF requires that the issuer, its officers, directors and 20% holders are not disqualified under Rule 503. The portal runs these checks before listing; the result is reflected in the Form C.
Advisers
Advisory Board members are not officers or employees, do not manage the Company and serve without cash or equity compensation.
Ongoing reporting
Annual report (Form C-AR)
Required by Reg CF: filed with the SEC and posted on this website within 120 days after each fiscal year end (by April 30), with financial statements and a discussion of results, until the Company no longer has to file.
Quarterly investor updates
A Company commitment beyond the rules: a written update each quarter on engineering, regulatory and financial progress, sent to every investor of record.
Milestones as they happen
Team hires, the FDA Pre-Submission filing and its outcome, and provisional patent filings are reported when they occur, to all investors at once.
Where to find them
Investors tab on this website, the offering page during the campaign, and EDGAR for every SEC filing.
How we communicate
Offering questions go on the portal
Reg CF requires that discussion of the offering happen through the portal’s public channel, so every investor sees the same answers. Ask there; we answer in writing.
Who speaks for the Company
Anyone who promotes this offering on the Company’s behalf, paid or unpaid, must identify themselves as such in every communication. Company representatives identify themselves in the portal Q&A.
Advertising limits
Outside the portal, the Company may state only the offering terms, factual information about its business, and a link to the portal. This website, emails and social posts follow that rule; the Form C controls where anything differs.
Testimonials and bonuses
Any investor statement the Company publishes is genuine, uncompensated and consented, and is not an indication that the offering is suitable for you. Bonus shares are exactly as filed in the Form C.
Privacy
This website collects no personal information. Investor identity, income and payment details are collected only by the portal and its escrow agent under their privacy policies.
Report a concern
Questions about conduct in this offering can be raised with the portal, with FINRA, or with the SEC Office of Investor Education and Advocacy.
Investor limits, cancellation and resale rules summarized from SEC Regulation Crowdfunding and the SEC Investor Bulletin on crowdfunding (limits as adjusted effective Sept. 20, 2022). Rules and figures may change; the Form C and the portal’s educational materials control.
Investor updates
What we will report, and when
Quarterly
A written update on engineering, regulatory and financial progress to every investor of record.
At each milestone
Team hires, FDA Pre-Submission filing and outcome, provisional patent filings, reported to all investors at once.
Annually
Form C-AR with financial statements, filed with the SEC and posted here by April 30 each year.
Risks
Ten things that could go wrong
A summary. The Form C contains the full risk factors, and they control.
S-WAVE™ is a laboratory prototype. It has never been used on a patient and its imaging performance has not been demonstrated.
Home use by consumers may face a higher bar than in-office devices. The FDA could require more testing than we expect, or decline.
This raise funds the path to an FDA submission, not a launch. Commercialization requires further funding that may not be available.
The Company depends on this offering to continue operating. One full-time employee; hires begin only at $1,000,000 raised.
Incumbents in dental imaging and remote monitoring are larger and better funded, and could enter at-home sub-surface imaging.
The $350 tray and $1-a-day subscription are plans; no customer has paid for S-WAVE™ and no supplier agreements exist.
Other parties hold patents in intraoral ultrasound. Freedom to operate has not been established; see the Form C.
No public market; resale is restricted for one year and may never be possible. Dividends are paid only if declared.
The Company depends on its CEO, who also holds roles at affiliated companies described in the Form C.
Early-stage medical-device investments fail often. Invest only what you can afford to lose.
Questions investors ask